Announcements Trials
Browse Landscape

Phase

Phase 1 58Phase 2 47Phase 1/2 21Phase 3 3Phase EARLY_PHASE1 1Phase 4 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Recurrence 1Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Panobinostat × Clear all
NCT04326764 2023-02-16

Panobinostat Maintenance After HSCT fo High-risk AML and MDS

Goethe University

Phase 3 Terminated
52 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01023308 2020-03-17

PANORAMA-1

Novartis

Phase 3 Completed
767 enrolled 17 charts
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01034163 2016-07-07

PATH

Novartis

Phase 3 Completed
41 enrolled 7 charts
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡